AI Article Synopsis

  • * Initial tumor growth was slow (1.0 to 4.9 years doubling time), but it accelerated significantly to 0.3 years in the final two months before surgery, prompting intervention.
  • * Pathological examination revealed that areas with more rhabdoid cells showed aggressive malignant features, while regions with fewer rhabdoid cells exhibited less malignancy, suggesting that volumetric analysis can effectively guide surgical decisions for potentially malignant meningiomas.

Article Abstract

The authors describe a case of rhabdoid meningioma (RM) in a 17-year-old boy that was determined by measuring the tumor volume during preoperative follow-up. The volume of the tumor located in the left occipital lobe, was measured every 1-5 months, using an image analysis software. The tumor volume doubling time (Td) ranged from 1.0 to 4.9 years in the first 11 months, but became 0.3 years in the last two months. The tumor grew rapidly in the last two months at which time surgery was performed. Pathological examination of the surgical specimen showed that the tumor contained rhabdoid cells (RCs). RCs were heterogeneously distributed in the tumor admixed with spindle-shaped cells. The areas where RCs were predominant had malignant histological features, with necrosis and high proliferation indices, whereas the areas with few RCs lacked the malignant features. The tumor grew slowly in the initial phase, possibly because components with low proliferation rates occupied most of the tumor. The tumor began to grow rapidly when the malignant component containing abundant RCs became predominant. To the authors' knowledge, this is the first report monitoring the volumetric change of RM periodically. Our investigation indicated that volumetric analysis is useful to decide surgical intervention of the meningiomas with potential malignancy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tumor
9
volumetric analysis
8
rhabdoid meningioma
8
preoperative follow-up
8
tumor volume
8
years months
8
tumor grew
8
areas rcs
8
rcs predominant
8
rcs
5

Similar Publications

Introduction: Antibody-drug conjugates (ADCs) trastuzumab-deruxtecan (T-DXd) and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and overall survival (OS) improvements over chemotherapy (CT) in pretreated hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low metastatic breast cancer (MBC). However, no direct comparison between the two exists, nor with the more recent datopotamab-deruxtecan (Dato-DXd).

Methods: We conducted a network meta-analysis (NMA) to compare efficacy and safety of T-DXd and SG in CT-pretreated HR+ and TN/HER2-low MBC and assess their benefit over standard CT, exploring also a comparison with Dato-DXd.

View Article and Find Full Text PDF

Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma.

Lung Cancer

December 2024

State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:

Background: Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of non-small-cell lung cancer. This study aims to compare the efficacy and safety of perioperative PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone in stage II-IIIB PLELC patients.

Patients And Methods: This retrospective study included stage II-IIIB PLELC patients.

View Article and Find Full Text PDF

Background: The upfront treatment of non-oncogene-addicted NSCLC relies on immunotherapy alone (ICI) or in combination with chemotherapy (CT-ICI). Genomic aberrations such as KRAS, TP53, KEAP1, SMARCA4, or STK11 may impact survival outcomes.

Methods: We performed an observational study of 145 patients treated with first-line IO or CT-ICI for advanced non-squamous (nsq) NSCLC at our institution tested with an extensive lab-developed NGS panel.

View Article and Find Full Text PDF

Ginsenoside Rh2 promotes cell apoptosis in T-cell acute lymphocytic leukaemia by MAPK and PI3K/AKT signalling pathways.

Nat Prod Res

December 2024

State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Fermentation Microbiology, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China.

T-cell acute lymphoblastic leukaemia (T-ALL) is a common childhood malignant tumour, which has poor prognosis and high recurrence rate. Ginsenoside Rh2 (GRh2), a bioactive ingredient of has significant anti-tumour effect. In this study, we found that gene expressions of Jurkat cells were significantly changed in the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) signalling pathways after 35 µm GRh2 treatment, involving in JUN, PIEN, AKT3 and MAPK8IP2.

View Article and Find Full Text PDF

Protocol for generating a co-culture of macrophages with breast cancer tumoroids.

STAR Protoc

December 2024

University Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, F-59000 Lille, France; Equipe Labellisée Ligue Contre le Cancer, Lille, France. Electronic address:

Cancer progression and treatment outcomes are heavily influenced by the tumor microenvironment (TME), especially through immune cell interactions. Here, we present a protocol for generating co-cultures of tumoroids with macrophages, either semi-liquid or Matrigel-embedded. We describe steps for macrophage preparation, co-culture establishment, and medium adjustments to support cell viability and function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!